Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Toxins (Basel) ; 12(7)2020 07 11.
Article in English | MEDLINE | ID: mdl-32664481

ABSTRACT

The pore-forming cytotoxin α-hemolysin, or Hla, is a critical Staphylococcus aureus virulence factor that promotes infection by causing tissue damage, excessive inflammation, and lysis of both innate and adaptive immune cells, among other cellular targets. In this study, we asked whether a virus-like particle (VLP)-based vaccine targeting Hla could attenuate S. aureus Hla-mediated pathogenesis. VLPs are versatile vaccine platforms that can be used to display target antigens in a multivalent array, typically resulting in the induction of high titer, long-lasting antibody responses. In the present study, we describe the first VLP-based vaccines that target Hla. Vaccination with either of two VLPs displaying a 21 amino-acid linear neutralizing domain (LND) of Hla protected both male and female mice from subcutaneous Hla challenge, evident by reduction in lesion size and neutrophil influx to the site of intoxication. Antibodies elicited by VLP-LND vaccination bound both the LND peptide and the native toxin, effectively neutralizing Hla and preventing toxin-mediated lysis of target cells. We anticipate these novel and promising vaccines being part of a multi-component S. aureus vaccine to reduce severity of S. aureus infection.


Subject(s)
Bacterial Toxins/pharmacology , Bacterial Vaccines/pharmacology , Hemolysin Proteins/pharmacology , Skin/drug effects , Staphylococcal Skin Infections/prevention & control , Staphylococcus aureus/drug effects , Vaccines, Virus-Like Particle/pharmacology , Animals , Antibodies, Bacterial/blood , Bacterial Toxins/immunology , Bacterial Vaccines/immunology , Disease Models, Animal , Epitopes , Female , Hemolysin Proteins/immunology , Humans , Immunogenicity, Vaccine , Jurkat Cells , Male , Mice, Inbred BALB C , Neutralization Tests , Skin/immunology , Skin/microbiology , Skin/pathology , Staphylococcal Skin Infections/immunology , Staphylococcal Skin Infections/microbiology , Staphylococcal Skin Infections/pathology , Staphylococcus aureus/immunology , Staphylococcus aureus/pathogenicity , Vaccination , Vaccines, Virus-Like Particle/immunology
SELECTION OF CITATIONS
SEARCH DETAIL